RET/papillary thyroid carcinoma 1 (PTC1) oncogene is frequently activated in human PTCs. It is characterized by the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of CCDC6. The aim of our work is to characterize the function of the CCDC6 protein to better understand the function of its truncation, that results in the loss of the expression of one allele, in the process of thyroid carcinogenesis. Here, we report that CCDC6 interacts with CREB1 and represses its transcriptional activity by recruiting histone deacetylase 1 and protein phosphatase 1 proteins at the CRE site of the CREB1 target genes. Finally, we show an increased CREB1 phosphorylation and activity in PTCs carrying the RET/PTC1 oncogene. Consistently, an increased expression of two known CREB1 target genes, AREG and cyclin A, was observed in this subgroup of thyroid papillary carcinomas. Therefore, the repression of CREB1 activity by CCDC6 has a critical function in the development of human thyroid papillary carcinomas carrying RET/PTC1 activation.
Introduction
The RET/papillary thyroid carcinoma (PTC) oncogene is activated in about 20% of PTC (Kondo et al., 2006) . RET/PTCs are chimeric genes generated by the fusion of the RET tyrosine kinase domain with the 5 0 terminal region of other genes. There are at least 15 types of RET/PTC rearrangements involving RET and 10 different genes. RET/PTC1 and RET/PTC3 are the most prevalent RET/PTC variants (Grieco et al., 1990; Santoro et al., 1994 Santoro et al., , 2006 . In RET/PTC1, the fusion occurs with the CCDC6 gene (Grieco et al., 1990 ) after a chromosomal inversion [inv (10) (q11.2q21)] (Pierotti et al., 1992) .
All the genes fused to RET are ubiquitously expressed and, therefore, are able to drive the expression of truncated forms of RET in thyroid follicular cells, which normally do not express it. Certainly, the inappropriate expression of RET/PTC in the thyroid follicular cells, the mislocalization of the RET-tyrosine kinase from the membrane to the cytoplasm, the absence of the extracellular regulatory region of RET, and the presence of coiled-coil domains in the RET-partner coding sequences, that favors the dimerization process, account for the oncogenic activity of the chimeric RET/PTC genes. The function of RET/PTC oncogene in thyroid carcinogenesis has been validated by in vitro and in vivo experiments. Indeed, PCCl 3 cells expressing the RET/PTC1 oncogene lose the differentiated phenotype, but are not tumorigenic. Equally, transgenic mice with thyroid-targeted expression of PTC1 developed thyroid carcinomas, indicating that the fusion has a primary function in the pathogenesis of the disease with which it is associated (Santoro et al., 1996) . RET/PTC rearrangements are specific for thyroid carcinomas of papillary histotype and are considered early events in the tumorigenesis process, as they are frequently found in clinically silent small PTCs (Viglietto et al., 1995) .
As the fusion of CCDC6 with RET results in the loss of the function of one allele, and in some cases, also of the normal unrearranged CCDC6 allele, it is reasonable to hypothesize that this loss might result in growth advantage during tumor progression. Therefore, it becomes important to elucidate the function of the CCDC6 gene product also in consideration that the CCDC6 gene has been reported to be fused to genes other than RET in thyroid and non-thyroid human neoplastic diseases (Kulkarni et al., 2000; Schwaller et al., 2001; Puxeddu et al., 2005; Drechsler et al., 2007) .
Earlier work has shown that CCDC6 gene product is an ubiquitously expressed 65 kDa nuclear and cytosolic protein, is phosphorylated by extracellular signalregulated protein kinase after serum stimulation (Grieco et al., 1994; Celetti et al., 2004) ; it has also been proposed as a proapoptotic factor (Celetti et al., 2004) . More recently, it has been shown that CCDC6 is involved in ATM-mediated cellular response to DNA damage, supporting the idea that the impairment of CCDC6 gene function might have a function in thyroid carcinogenesis (Merolla et al., 2007) . The aim of our work has been to further characterize the function of the CCDC6 protein first by searching for the interacting proteins. By a functional proteomic approach, we identified several proteins among which we selected the CREB1 protein because of its relevance in the regulation of thyroid cell proliferation (Kimura et al., 2001) . First, we have confirmed the interaction between CCDC6 and CREB1 and then, we showed that CCDC6 is responsible for the transcriptional repression of CREB1 target genes, promoting HDAC1 activity. Finally, we report that the repression of the CREB1 activity is achieved by CCDC6 activating the PP1 phosphatase that is able to dephosphorylate CREB1 at Ser133.
Results

CCDC6 protein binds CREB1
To identify CCDC6-interacting proteins, a proteomic approach was used. To achieve this, we transiently transfected B-CPAP cells with a V5-tagged CCDC6-expression vector. Nuclear protein lysates were immunoprecipitated with anti-V5 antibodies, fractionated by SDS-PAGE, and visualized by ammoniacal silver staining (Supplementary Figure 1) . Single components of the immunoprecipitated complexes were digested with trypsin and identified by mass spectrometry (Talamo et al., 2003) . In Supplementary Table 1, we report some representative CCDC6-interacting proteins. Among them, we focused our attention on the CREB1 protein because of its relevance in thyroid cell proliferation. Indeed, thyroid cells are dependent for growth and differentiation on thyrotropin that through the activation of its receptor stimulates the c-AMP pathway, eventually leading to CREB1 phosphorylation and activation of its transcriptional activity (Kimura et al., 2001) .
The following step of our work was to validate the CCDC6-CREB1 interaction by a pull-down assay. For this purpose, the GST-CCDC6 fusion protein was tested for its ability to bind CREB1 and the other members of the CREB protein family in vitro. Protein lysates from B-CPAP cells, a thyroid papillary cancer line, were incubated with GST-CCDC6 or GST alone, and the bound proteins were then analyzed by western blot using antibodies against the different CREB family proteins. As shown in Figure 1a , specific bands were observed in the GST-CCDC6 lane when the blots were incubated with antibodies versus CREB1 and ATF2. Conversely, no specific bands were observed with antibodies versus the other members of the CREB family, and when TCEs were incubated with GST protein used as control. These data indicate a specific and direct physical interaction of CCDC6 with CREB1 and ATF2, but not with other CREB family proteins, at least in these experimental conditions.
To verify that the CCDC6/CREB1 interaction occurs also in cultured cells, protein lysates from B-CPAP cells, which express the endogenous CCDC6 protein, were immunoprecipitated with anti-CREB1 antibodies and immunoblotted with anti-CCDC6 antibodies. As shown in Figure 1b , specific bands were detected, indicating that CCDC6 and CREB1 form complexes in cultured cells. The reciprocal experiment confirmed the interaction (Figure 1b) . To investigate whether the portion of CCDC6 included in the RET/PTC1 oncoprotein is crucial for the binding of CREB1, we performed co-immunoprecipitation experiments in B-CPAP cells transiently transfected with the CCDC6 (1-101) aa deleted mutant. Protein lysates were first immunoprecipitated with anti-Myc antibody, and then the filters were immunoblotted with anti-Myc and anti-CREB1 antibodies. As shown in Figure 1c 
CCDC6 inhibits the transcriptional activity of CREB1
To understand the functional consequences of the interaction of CCDC6 with CREB1, we investigated whether CCDC6 can be directly involved in the transactivating activity of CREB1. Therefore, we transfected B-CPAP cells with a CRE-luc reporter gene (De Angelis et al., 2003) in which tandem three CRE universal sites were fused upstream to a luciferase cDNA together with increasing amounts of CCDC6 in the presence of CREB1. As shown in Figure 2a , the over-expression of CREB1 activated the reporter more than sixfold, whereas cotransfection of CCDC6 resulted in a decrease of CREB-mediated transcriptional activity in a dose-dependent manner. Indeed, a decrease of 20 and 70% was obtained when 1 and 5 mg of CCDC6 were co-expressed with CREB1, respectively, whereas CCDC6 alone slightly modified the CRE-luc reporter basal activity. As expected, the CCDC6 (1-101) mutant does not inhibit the CREB activity (Figure 2a ).
CCDC6 reduces CREB binding to CRE element
To unveil the biochemical mechanisms underlying the negative regulation of CREB1 target gene transcription by CCDC6, we investigated by electrophoretic mobility shift assay the effect of CCDC6 on the binding of CREB to the CRE element. Nuclear extracts from B-CPAP cells over-expressing CCDC6 or from control cells were incubated with a CRE radiolabelled oligonucleotide. As shown in Figure 2b To confirm whether the binding is really due to CREB1 protein, supershift experiment was performed using specific antibodies directed against CREB1 protein. As shown in Figure 2b , the complex was specifically supershifted by the CREB1 antibodies, indicating that the complex consisted mainly of CREB1 protein. To verify these data in cells, we investigated by chromatin immunoprecipitation (ChIP) whether CCDC6 protein binds a CREB1 target gene promoter, such as AREG, a member of an EGF-like growth factor (Berasain et al., 2007) . Therefore, the thyroid papillary cancer cell line TPC1, which harbors the RET/PTC1 rearrangement and has lost the normal unrearranged (1-101) deleted mutant constructs. TCEs were prepared and equal amounts of proteins were immunoprecipitated with antiMyc or anti-CREB1. Then, the immunocomplexes were analyzed by western blotting using the indicated antibodies. IgG indicates negative control of immunoprecipitation using an unrelated antibody.
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comparison with the control cells, indicating that the binding of CREB1 to the AREG promoter is reduced by CCDC6 expression. Conversely, no amplification was observed when primers for the control promoter GAPDH were used. These results indicate that CCDC6 reduces CREB1 binding to AREG promoter.
Subsequently, we evaluated the expression of AREG by real-time PCR in parental and expressing-CCDC6 TPC1 cells. In CCDC6-expressing cells, the AREG expression was reduced about 40% in comparison with parental cells, confirming that CCDC6 reduces the expression of the AREG gene (Figure 2e ). 
CCDC6 reduces the phosphorylation of CREB1 at Ser133
It is known that CREB1 activity is also dependent on its phosphorylation status (Gonzalez and Montminy, 1989) . In particular, phosphorylation at Ser133 represents a critical modification for CREB1 activity. Therefore, we investigated whether CCDC6 could reduce the CREB1 activity modifying the phosphorylation status of Ser133. To achieve this, TPC1 cells were transfected with CCDC6 and the proteins were analyzed by western blot with antibodies against pSer133 CREB1 and against total CREB1. As shown in Figure 3a (left panel), the amount of phosphorylated CREB1 is lower in CCDC6-expressing cells in comparison with control cells. Conversely, the use of antibodies versus the CREB1 protein revealed equal amount of CREB1 in both the cells. These data indicate that the expression of CCDC6 reduces the phosphorylation status of CREB1, regulating its transcriptional activity. To further show that CCDC6 expression is able to reduce the phosphorylation at Ser133 of CREB1 protein, the endogenous CCDC6 gene expression was transiently silenced transfecting B-CPAP cells with small-interfering RNAs (CCDC6i-345). As shown in Figure 3a (right panel), silencing of CCDC6 gene expression increased the phosphorylation status of CREB1, in comparison with the same cells treated with CCDC6 physically interacts with PP1 on the AREG promoter PP1, PP2A, and PP2B, belonging to the PPP family of Ser/Thr protein phosphatases, participate in regulating many important physiological processes, such as cell cycle control and regulation of cell growth and division regulation (Klumpp and Krieglstein, 2002; Terrak et al., 2004; Bennett, 2005; Trinkle-Mulcahy and Lamond, 2006; Han et al., 2007; Wang et al., 2008; Virshup and Shenolikar, 2009 ). It has also been reported that CREB1 is inactivated by PP1 through dephosphorylation at Ser133 (Hagiwara et al., 1992) . To understand the mechanism by which CCDC6 is able to modify the phosphorylation status of CREB1, therefore, we hypothesized that a possible interaction of CCDC6 with PP1 could account for this CCDC6-mediated effect. We first investigated whether CCDC6 was able to physically interact with PP1. To this aim, B-CPAP cells were transiently transfected with the CCDC6-expressing vector, and protein lysates were immunoprecipitated with the indicated antibodies. As shown in Figure 3b , PP1 and CREB1 co-immunoprecipitated indicating that PP1 forms a complex with CCDC6 and CREB1.
To investigate whether the physical interaction between CCDC6, PP1, and CREB1 takes place on the human AREG promoter, we first evaluated whether PP1 protein binds the AREG promoter in cultured cells and then whether the binding is influenced by CCDC6 expression, by ChIP assay using antibodies raised versus the PP1 protein. PP1 precipitated AREG promoter region in CCDC6-expressing TPC1 cells (Figure 3c ) and in B-CPAP cells (data not shown). Indeed, the immunoprecipitated DNA-chromatins were analyzed by semiquantitative PCR and quantitative reverse transcription PCR (qRT-PCR) using specific primers spanning the AREG promoter region containing CRE elements. The results shown in Figure 3c indicate that PP1 protein binds the AREG promoter region and that this binding was increased after CCDC6 expression.
To determine whether CCDC6, PP1, and CREB1 occupy this AREG promoter region all together, ReChIP experiments were performed in CCDC6-expressing TPC1 cells with the indicated antibodies. The results showed that PP1, CREB1, and CCDC6 participate to the same DNA-bound complex on AREG promoter (Figure 3d, upper panel) . It is noteworthy that the same results were obtained in B-CPAP cells expressing the endogenous CCDC6 protein (Figure 3d , lower panel).
CCDC6 physically interacts with HDAC1
Recently, it has been shown that PP1 can be targeted to CREB1, for efficient dephosphorylation, through binding of PP1 to HDAC1 (Canettieri et al., 2003) or HDAC8 proteins (Gao et al., 2009) . HDACs catalyze the removal of acetyl groups from core histones (Marks et al., 2001) , inducing local condensation of chromatin. Therefore, HDACs are generally considered repressors of transcription (Marks et al., 2001) .
Our data strongly suggested an interaction between CCDC6 and the proteins of HDAC family. To test this hypothesis, protein lysates from B-CPAP cells were incubated with GST-CCDC6 or GST alone for 2 h, and then a pull-down assay was performed. As shown in Figure 4a , HDAC1 was able to interact with GST-CCDC6, and not with GST alone. Then, we confirmed the CCDC6-HDAC1 interaction also by co-immunoprecipitation experiment between the endogenous proteins in B-CPAP cells (Figure 4b ).
CCDC6 interacts with HDAC1 on the AREG promoter
To determine whether HDAC1 binds the AREG promoter, ChIP experiments were performed in wt and in CCDC6-expressing TPC1 cells. As expected, CCDC6 binds AREG promoter (Figure 4c ). HDAC1 is also able to bind this promoter, and its occupancy increases after CCDC6 expression (Figure 4c) .
Subsequently, to determine whether CCDC6 occupies the AREG promoter together with HDAC1, ChIP, and Re-ChIP experiments were performed in TPC1 cells wt and transfected with the CCDC6-expressing vector. The anti-CCDC6 were released, reimmunoprecipitated with anti-HDAC1 (Re-ChIP), and then analyzed by semiquantitative PCR and qRT-PCR. The results, shown in Figure 4c lower panel, reveal that the antibodies against HDAC1 precipitate the AREG promoter in TPC1-CCDC6 cells and not in the control ones after their release from anti-CCDC6, indicating that CCDC6 occupies this region with HDAC1 (Figure 4c ). The same results were obtained in B-CPAP cells expressing the endogenous CCDC6 protein (data not shown).
Taken together, these results indicate that CCDC6 binds the human AREG promoter and that participates in the same DNA-bound complex that contains HDAC1.
CCDC6 expression is correlated with AREG promoter deacetylation
The fact that CCDC6 and HDAC1 are present on the same CRE region of the AREG promoter suggests that HDAC1 participates in the CCDC6-mediated repression of CREB1 target genes. Therefore, we analyzed the acetylation status of histones H3 at the AREG promoter by ChIP assays. Parental and CCDC6-expressing TPC1 cells were immunoprecipitated with antibodies against acetylated-histones H3. The immunoprecipitated DNAchromatin was subsequently analyzed by semiquantitative PCR and qRT-PCR using primers specific for the AREG promoter. A lower amplification was observed in the CCDC6-expressing cells in comparison with the control cells (Figure 4d ), indicating that CCDC6 expression is associated with a strong decrease in the levels of acetylated-histones H3 at the AREG promoter. No amplification was observed with antiIgG precipitates.
CCDC6 represses CREB1 activity V Leone et al CCDC6 requires HDAC1 activity to repress CREB1 target gene transcription The data shown above prompted us to investigate whether CCDC6 could mediate the repression of CREB1 target gene transcription by the recruitment of HDACs. Therefore, we first analyzed HDAC activity in nuclear extracts from B-CPAP over-expressing and not CCDC6. As shown in Figure 5a , CCDC6 expression increased the HDAC activity in a dose-dependent manner. To confirm these results, we analyzed HDAC activity in the same cells in the presence or absence of TSA (300 nM for 24 h), which specifically inhibits HDACs ( Figure 5b ). As expected, in the presence of TSA, the HDAC activity was inhibited, in both the empty and CCDC6-expressing vector-transfected cells. However, the inhibition of HDAC activity was higher in the CCDC6 over-expressing cells with respect to the control cells. Finally, we analyzed the effects of TSA in the CCDC6-mediated repression of CREB1 target genes CCDC6 represses CREB1 activity V Leone et al through a luciferase assay on the CRE-luc reporter construct in the presence of CCDC6 and CREB1 after TSA treatment. As shown in Figure 5c , the CRE-luc basal activity was increased by CREB1 expression, whereas it was significantly reduced by co-expression of CCDC6 as earlier shown. The treatment with TSA reduced the inhibitory effect of CCDC6 (Figure 5c ).
CCDC6 inhibits CREB1 activity also in human PTCs
To evaluate whether the relationship between CCDC6 over-expression and CREB1 activity defined in tumor cell lines can occur also in vivo, we analyzed the levels of the phosphorylated CREB1 protein at Ser133 and the consequently CREB1 transcriptional activity in normal thyroid, in several PTCs carrying either RET/PTC1 or BRAF mutations, and in PTCs in which no known genetic lesion was detected. As shown in Figure 6a , the levels of pCREB1 at Ser133 were higher in PTCs carrying the RET/PTC1 oncogene, which did not express CCDC6 in comparison with normal thyroid tissue and PTCs carrying other genetic lesions than RET/PTC1 and expressing CCDC6. Then, we analyzed the expression of CREB1 target genes, AREG and Cyclin A. Consistent with these results, AREG and Cyclin A gene expression, evaluated by qRT-PCR, essentially paralleled the level of phosphorylation of CREB1 (Figure 6b) . Surprisingly, the levels of specific CREB1 mRNA were lower in PTCs compared with normal thyroid (Supplementary Figure 3) . Analogous results have been described earlier (Luciani et al., 2003) . Post-translational mechanisms, therefore, account for the increased CREB1 protein levels in PTCs.
Therefore, these results clearly indicate that the reduced expression of CCDC6, that follows the RET/ PTC1 rearrangement (Sheils et al., 2000) , results in an increased CREB1 phosphorylation and transcriptional activity also in vivo.
Discussion
We have investigated the physiological function of CCDC6 in thyroid cellular functions searching for the interacting proteins. Among the proteins binding to CCDC6 identified by a proteomic approach, we focused our attention on the CREB1 protein as CREB1 activation represents the final step of the thyrotropin pathway that is critical for thyroid cell growth and differentiation. We first showed a physical interaction between CCDC6 and CREB1, but not with the other members of the CREB family. Then, we showed that CCDC6 binds CRE element present in target genes and reduces CREB1 binding to these sequences. Subsequently, in the attempt to verify the functional consequences of this interaction, we showed that the expression of CCDC6 results in a decreased CREB1 activity. Consequently, our efforts were finalized to the comprehension of the mechanism by which CCDC6 is able to inhibit the CREB1 transcriptional activity.
It is known that the phosphorylation is critical for CREB1 activity, and that CREB1 is dephosphorylated by PP1. Our results show that CCDC6 is able to bind PP1 leading to a reduced CREB1 phosphorylation at the critical Ser133. The reduced CREB1 phosphorylation is 
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V Leone et al also associated to a reduced binding of CREB1 to CRE elements. It is likely that CCDC6 protein exerts a critical function in recruiting PP1 to CREB1. In fact, it is known that PP1 does not have good substrate specificity, and that the PP1-interacting proteins not only localize PP1 to different cellular compartments, but can also deliver PP1 to close proximity of potential substrates, increasing PP1 substrate specificity and catalytic efficiency (Hu et al., 2006) . Consistently, it has been recently reported that HDAC1 interacts with PP1 and is critical for the efficient action of PP1 on CREB1 (Canettieri et al., 2003) . These data and the interaction between PP1 and CCDC6, showed in our experiments, suggested a possible interaction also between HDAC1 and CCDC6 that we have analyzed and confirmed. Moreover, we have shown that this interaction occurs at the level of the CREB1 responsive promoters, and that the CCDC6 expression increases HDAC1 activity first resulting in a reduced acetylation of the histone H3 at this region, and then, in a reduced transcription of the CREB1 responsive genes. Therefore, we hypothesize that PP1, CREB1, HDAC1, and CCDC6 form a unique complex in which the expression of CCDC6 works as a negative modulator of the CREB1 activity by increasing the PP1 activity on CRE element that leads to a decreased binding of CREB1 to the responsive regions. Moreover, CCDC6 inhibits CREB1 activity by activating HDAC1 that results in a decreased acetylation status of histone H3 at the CREB1 responsive promoters. All these results, showing that CCDC6 is able to reduce CREB1 activity, account for the inhibition of cell growth induced by CCDC6, as already shown (Merolla et al., 2007) .
We finally showed that the reduced CCDC6 expression, as it occurs in human PTCs carrying the RET/ PTC1 oncogene, leads to an increased CREB1 activity. This could result in a higher proliferation rate that associated with other mitogenic stimuli, as that of the RET/PTC activity, may lead to thyroid cell malignant transformation.
Therefore, all the data reported here let us to propose CCDC6 as a tumor suppressor in thyroid carcinogenesis inhibiting the CREB1-dependent gene expression.
Materials and methods
Cell cultures and transfection B-CPAP is a cell line obtained from a differentiated PTC. Mutations of H-ras, PTC, and trk were not observed (Fabien et al., 1994) . TPC1 cells are derived from PTC, which harbors the RET/PTC1 rearrangement and have lost the expression of the normal unrearranged CCDC6 allele. B-CPAP and TPC1 cells were maintained as reported elsewhere (Dettori et al., 2004; Merolla et al., 2007) . B-CPAP cells were transfected by 
Expression constructs
The expression CCDC6 and mutant CCDC6 (1-101) plasmids and small-interfering RNAs (CCDC6i-345) have been described elsewhere (Celetti et al., 2004; Merolla et al., 2007) . The expression plasmid pCMVSPORT6-CREB1 was from Invitrogen (Carlsbad, CA, USA). The GST-CCDC6 wt construct was obtained by amplifying the entire coding sequence (nt 1-1791) by PCR and then subcloned in the BamH1-EcoR1 restriction sites of pGEX2TK (Amersham, Rainham, UK).
In vitro proteins translation and pull-down assay GST pull-down experiments were carried out as reported elsewhere (Pierantoni et al., 2007) .
Protein extraction, western blotting, and immunoprecipitation assays Protein extraction, western blotting, and co-immunoprecipitation procedures were carried out as reported elsewhere (Fedele et al., 2005) . The Abs used for immunoprecipitation and western blotting were anti-CCDC6 (Celetti et al., 2004) , anti-CREB1, and anti-HDAC1(06720) (Upstate Biotechnology Inc., Lake Placid, NY, USA); anti-Myc(9E10), anti-ATF1, anti-ATF2, anti-ATF3, anti-CREM1, anti-CREB2, anti-PP1, and anti-a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-pCREB Ser133 (Cell Signaling Technology, Inc., Danvers, MA, USA).
Transactivation assay
In the luciferase transactivation assay, B-CPAP cells were transiently transfected with the reporter construct (De Angelis et al., 2003) . Co-transfections were carried out in the presence of 200 ng of reporter construct and 500 ng of Renilla construct and of 5 mg of CCDC6 or 2 mg of pCMVSport6-CREB1 with or without the indicated amounts of CCDC6 wt or mutant CCDC6 (1-101) constructs. Luciferase and Renilla activities were measured with the dual-luciferase reporter assay kit (Promega, Madison, WI, USA).
Electrophoretic mobility shift assay and supershift assay Electrophoretic mobility shift assay was performed as described earlier (Pierantoni et al., 2006) . CREB consensus oligonucleotide probe was from Santa Cruz Biotechnology Inc (TransCruz Gel Shift Oligonucleotides). A 200-fold molar excess of unlabelled oligonucleotide was added as specific competitor. For supershift analyses, samples were preincubated, on ice for 2 h, with 2 mg of CREB1 antibodies.
ChIP and Re-ChIP assays After transfection, chromatin samples were processed for ChIP and Re-ChIP experiments as reported elsewhere (Pierantoni et al., 2006) . Samples were subjected to immunoprecipitation with the following specific antibodies: anti-CCDC6 (Celetti et al., 2004) , anti-CREB1, anti-HDAC1(06720), anti-acetylHistone-H3, (Upstate Biotecnology); anti-PP1 (Santa Cruz Biotechnology Inc.). Detailed primer sequences are available as Supplementary Information.
RNA extraction, cDNA preparation, semiquantitative, and qRT-PCR Total RNA isolation, RT-PCR, and qRT-PCR from human tissues or from cells were performed as described earlier (De Martino et al., 2009 
